Image Credit: ProBio Inc. ProBio Inc, a contract development and manufacturing organization (CDMO) that is also known as GenScript ProBio, will be growing its plasmid DNA (pDNA) and viral vector manufacturing services by opening a new 128,000 square-foot plant in Hopewell, NJ.1 This new facility will operate as the hub for…
-
-
PC: How are changing reimbursement models impacting patient access to therapies in the space? As you know, even if a drug were to make it to market, questions remain as to whether it will be covered by insurance or even added to a national preferred formulary, making it difficult for…
-
Image Credit: Adobe Stock Images/iDoPixBox.com When it comes to the treatment of unresectable locally advanced stage III non–small cell lung cancer (NSCLC), the standard of care process features definitive chemoradiotherapy, followed by maintenance immunotherapy with durvalumab. In these instances, the obstacle is durvalumab’s cost of use in health systems, along…
-
DIA 2024: Gareth Dabbs of IQVIA Discusses Challenges With Clinical Technology In an interview with editor Andy Studna at DIA 2024, Dabbs, vice president, global product strategy, IQVIA highlights challenges with tech overload and how stakeholders can choose which solution(s) are best for their studies. Exploring the Connection Between Orange…
-
Image Credit: Adobe Stock Images/Nina.com Ascidian Therapeutics, a biotech company, has entered a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon-editing therapeutics that target neurological diseases.1 Ascidian—whose efforts revolve around rewriting RNA—has an RNA exon editing platform that is intended to further the…
-
The Potential of CAR T Therapies: Q&A with Ying Huang Legend Biotech revealed data collected from the CARTITUDE-2 Cohort D study at ASCO 2024 in Chicago in late May and early June of this year. The study is testing the ability of Carvykti to treat patients with relapsed/refractory multiple myeloma.…
-
What the Leaders of the Most Effective Teams Know Findings from hundreds of interviews of exceptional pharma leaders around the world. Global Mortality and Disability from Type 1 Diabetes Have Decreased Global mortality fell 13 times faster in countries with a high sociodemographic index compared with countries with a low-middle…
-
In this exclusive PC Podcast interview, Mark Bouck, chairman and CEO of PharmAlliance, a pharmaceutical and life sciences services platform, dives into: How PharmAlliance’s acquisition of Complete Health Economics Outcomes Research Solutions (CHEORS) helps expand global reach The platform’s biggest goal to when it comes to CHEORS and market access…
-
Image Credit: Adobe Stock Images/MPStudio.com Abzena, a contract development and manufacturing organization (CDMO) for complex biologics and bioconjugates, and Argonaut Manufacturing Services, Inc., a current good manufacturing practice (cGMP) CDMO that operates in the diagnostics and biopharmaceutical and diagnostics sectors, have decided to partner up to design a fully integrated…
-
Image Credit: Adobe Stock Images/iKatod.com As part of the company’s commercial plan, Bora Pharmaceuticals Co., Ltd., a contract development and manufacturing organization (CDMO), will be acquiring Emergent BioSolutions’ 87,000 square-foot sterile manufacturing facility in Baltimore-Camden, MD.1 The current site’s staff will also have the option to join the Bora team…